NOTCH1 and myopathy: This was an impressive finding as a number of glucocorticoid sensitisers are specific to a particular subtype of ALL, such as the γ-secretase inhibitor DBZ, which specifically sensitises glucocorticoid-resistant T-ALL with activated NOTCH1 mutations.44 Glucocorticoid use is associated with a number of side effects such as infection, osteonecrosis, psychosis and myopathy.50–54 Therefore, if GCS-3 is able to potentiate the effects of glucocorticoids in glucocorticoid-sensitive ALL, as seen with ALL-54, lower doses of glucocorticoids may be administered, which will reduce side effects.